MKI67 and neoplasm: Despite some mechanistic changes, the combination of cetuximab with gemcitabine had little effect on 18F-FLT uptake, Ki-67, EGFR protein level, or tumor growth delay in comparison to cetuximab monotherapy, suggesting that there is little benefit to adding gemcitabine to the treatment regime when a highly effective dose of cetuximab is used.